BLLN (BillionToOne) Non Operating Income: $-19.5 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLLN BillionToOne Inc BLLN
15 GF Score
Price $95.05
! 4 Warning Signs
View Full Analysis

What is BillionToOne Non Operating Income?

BillionToOne BLLN -0.25% 15 Non Operating Income is $-19.5 Mil as of Jun. 2026. GuruFocus rates BLLN with a GF Score™ of 15/100. The stock has 4 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. BillionToOne's Non Operating Income for the three months ended in Jun. 2026 was $-2.7 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $-19.5 Mil.

BillionToOne Non Operating Income Related Terms

BillionToOne Non Operating Income Historical Data

* Premium members only.

The historical data trend for BillionToOne's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BillionToOne Non Operating Income Chart

BillionToOne Annual Data
Trend Dec23 Dec24 Dec25
Non Operating Income
-13.36 2.17 -15.92

BillionToOne Quarterly Data
Dec23 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only -0.02 -5.57 -7.29 -3.96 -2.67
BLLN
15GF Score
BillionToOne Inc BLLN
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BillionToOne Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $-19.5 Mil mean?
BillionToOne (BLLN) has a Non Operating Income of $-19.5 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on BillionToOne and its competitors.
Is BillionToOne's Non Operating Income too high?
BillionToOne's current Non Operating Income is $-19.5 Mil. Overall, BillionToOne has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's Non Operating Income compare to TWST and SHC?
BillionToOne's Non Operating Income of $-19.5 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Medical Diagnostics & Research company?
A good Non Operating Income depends on the Medical Diagnostics & Research industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on BillionToOne and its competitors. BillionToOne's current Non Operating Income is $-19.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current Non Operating Income of $-19.5 Mil. The current Non Operating Income is $-19.5 Mil. BillionToOne's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For BillionToOne (BLLN), the current Non Operating Income is $-19.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BillionToOne Business Description

Address 1035 O’Brien Drive, Menlo Park, CA, USA, 94025
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
15GF Score

Get the complete analysis for BLLN

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$95.05
Price